Loading...
Loading...
HROW| Name | Value |
|---|---|
| Revenues | 36.4M |
| Cost of Revenue | 11.3M |
| Gross Profit | 25.1M |
| Operating Expense | 29.5M |
| Operating I/L | -4.5M |
| Other Income/Expense | -4.8M |
| Interest Income | 0.0M |
| Pretax | -9.7M |
| Income Tax Expense | -0.5M |
| Net Income/Loss | -9.1M |
Harrow Health, Inc. is an ophthalmic-focused healthcare company that operates ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business, and markets DEXYCU for post-operative inflammation treatment. The company also holds equity interests in Surface Ophthalmics, Inc., a pharmaceutical company focusing on ocular surface disease therapeutics; Melt Pharmaceuticals, Inc., specializing in non-intravenous sedation and anesthesia therapeutics; and Eton Pharmaceuticals, Inc., engaged in drug product development and commercialization. Harrow Health, Inc. generates revenue through the sale of pharmaceutical products, equity interests in other pharmaceutical companies, and royalty rights in clinical stage drug candidates developed by its partners.
